

To: (10)(2e) <(10)(2e)@rivm.nl>; (10)(2e) <(10)(2e)@sanquin.nl>; (10)(2e) <(10)(2e)@sanquin.nl>; (10)(2e) <(10)(2e)@sanquin.nl>; (10)(2e) <(10)(2e)@rivm.nl>; (10)(2e) <(10)(2e)@phe.gov.uk>; (10)(2e) <(10)(2e)@phe.gov.uk>
Cc: (10)(2e) <(10)(2e)@ndcls.ox.ac.uk>
From: (10)(2e)
Sent: Sat 10/31/2020 7:32:36 PM
Subject: RE: SCoV-2 virusneutralization in UK and in NL
Received: Sat 10/31/2020 7:34:56 PM


Thank you so much – this is great and I will get a draft circulated shortly.
 Best wishes (10)(2e)

From: (10)(2e) <(10)(2e)@rivm.nl>
Sent: 31 October 2020 18:44
To: (10)(2e) <(10)(2e)@nhsbt.nhs.uk>; (10)(2e) <(10)(2e)@sanquin.nl>; (10)(2e) <(10)(2e)@sanquin.nl>; (10)(2e) <(10)(2e)@sanquin.nl>; (10)(2e) <(10)(2e)@rivm.nl>; (10)(2e) <(10)(2e)@phe.gov.uk>; (10)(2e) <(10)(2e)@phe.gov.uk>
Cc: (10)(2e) <(10)(2e)@ndcls.ox.ac.uk>
Subject: RE: SCoV-2 virusneutralization in UK and in NL

Hi,

I must have overlooked that request (not so difficult seeing that 60% of my inbox is in a permanent unread situation).

Please find the details here (papers attached):



Cheers (10)(2e)

From: (10)(2e) <(10)(2e)@nhsbt.nhs.uk>
Sent: zaterdag 31 oktober 2020 19:08
To: (10)(2e) <(10)(2e)@rivm.nl>; (10)(2e) <(10)(2e)@sanquin.nl>; (10)(2e) <(10)(2e)@sanquin.nl>; (10)(2e) <(10)(2e)@sanquin.nl>; (10)(2e) <(10)(2e)@rivm.nl>; (10)(2e) <(10)(2e)@phe.gov.uk>; (10)(2e) <(10)(2e)@phe.gov.uk>
Cc: (10)(2e) <(10)(2e)@ndcls.ox.ac.uk>
Subject: RE: SCoV-2 virusneutralization in UK and in NL

Thanks (10)(2e) for following this up. I am keen to do this but was awaiting to get more information re methods... left it after did

not got any responses after 2nd reminder. However, I assume it might be difficult to distribute SOPs (especially when yours is likely in Dutch!), so if you could respond to these questions and provide a reference for your method, I will continue with this work. I have most of these details already for PHE method from (10)(2e)

- Cell line used
- Virus strain used (sequence available/ GenBank number)
- Amount of virus used
- How long incubated
- Overlay used in case of plaque assay

Best wishes (10)(2e)

From: (10)(2e) <(10)(2e)@rivm.nl>

Sent: 31 October 2020 15:05

To: [REDACTED] <[REDACTED]>; [REDACTED] <[REDACTED]>; [REDACTED] <[REDACTED]>; [REDACTED] <[REDACTED]>; [REDACTED] <[REDACTED]>;
[REDACTED] <[REDACTED]>; [REDACTED] <[REDACTED]>; [REDACTED] <[REDACTED]>; [REDACTED] <[REDACTED]>; [REDACTED] <[REDACTED]>;
[REDACTED] <[REDACTED]>; [REDACTED] <[REDACTED]>; [REDACTED] <[REDACTED]>

Cc: (10)(2e) <(10)(2e)@ndcls.ox.ac.uk>


Subject: RE: SCoV-2 virusneutralization in UK and in NL

Hi (10)(2e)

I was wondering whether you did manage to draft the short note?


Best wishes (10)(2e)


The diagram illustrates a sequence of 10 nodes arranged in a grid. The nodes are labeled with $(10)(2e)$ and $(10)(2e)$. The nodes are arranged in a grid with 5 rows and 2 columns. The first row has nodes $(10)(2e)$ and $(10)(2e)$. The second row has nodes $(10)(2e)$ and $(10)(2e)$. The third row has nodes $(10)(2e)$ and $(10)(2e)$. The fourth row has nodes $(10)(2e)$ and $(10)(2e)$. The fifth row has nodes $(10)(2e)$ and $(10)(2e)$. The nodes are connected by arrows in a sequence from top-left to bottom-right.




dubbel

	(10)(2e)		(10)(2e)				
	(10)(2e)		(10)(2e)		(10)(2e)	(10)(2e)	(10)(2e)
(10)(2e)		(10)(2e)		(10)(2e)		(10)(2e)	
(10)(2e)	(10)(2e)						






dubbel



$(10)(2e)$ $(10)(2e)$ $(10)(2e)$ $(10)(2e)$ $(10)(2e)$ $(10)(2e)$

dubbel

dubbel



dubbel